Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IOV-5001

Other · developed by IOVANCE BIOTHERAPEUTICS

Phase 1/2 Most advanced trial

IOVA Developer

1 Registered trials

What is IOV-5001?

IOV-5001 is an investigational drug studied in Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC).

At a glance

Drug type: Other
Therapy area: Oncology
Developer: IOVANCE BIOTHERAPEUTICS (IOVA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07743723	Phase 1/2	Advanced Solid Tumors	Not yet recruiting	IOVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsColorectal CancerHead and Neck Squamous Cell CarcinomaMetastatic Solid TumorsNon-Small Cell Lung CancerTriple Negative Breast Cancer (TNBC)Unresectable Solid Tumor

More from IOVANCE BIOTHERAPEUTICS

Lifileucel FDA approved IOV-2001 Phase 1 IOV-3001 Phase 1/2 IOV-4001 Phase 1/2

Sources

ClinicalTrials.gov NCT07743723

Updated Oct 3, 2026. Something wrong or missing? Report it on the IOVA page.

Follow IOVA, the company behind IOV-5001

See IOVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IOVA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z